Navigation Links
AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Date:11/7/2008

PASADENA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $23,000, or break even per share basic and diluted, for the three months ended September 30, 2008, compared with a net loss of $8,000, or break even per share basic and diluted, for the three months ended September 30, 2007. For the nine months ended September 30, 2008, the net loss was $216,000, or $0.01 per share basic and diluted, compared with net loss of $62,000, or break even per share basic and diluted for the same period in 2007. As of September 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC during the third quarter were unchanged from the same period prior year." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, MBP8298, if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. During the third quarter just completed, BioMS announced the product was granted fast track designation by the FDA and that it had received a milestone payment from Eli Lilly for successfully passing an interim analysis for safety and futility in its pivotal phase II/III trial of MBP8208 for treatment of secondary progressive multiple sclerosis. We expect the final trial data will be available during the second half of 2009.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended Nine months ended

September 30, September 30,

2007 2008 2007 2008

Revenue $59,000 $57,000 $219,000 $225,000

Costs and expenses:

Cost of revenue 9,000 1,000 20,000 29,000

Research and

development 7,000 3,000 95,000 93,000

Selling, general

and administrative 163,000 125,000 532,000 511,000

Total costs and

expenses 179,000 129,000 647,000 633,000

Interest income 112,000 51,000 335,000 195,000

Minority interest

in joint venture - (2,000) 6,000 (3,000)

Other income - - 25,000 0

112,000 49,000 366,000 192,000

Net loss ($8,000) ($23,000) ($62,000) ($216,000)

Net loss per share -

basic ($0.00) ($0.00) ($0.00) ($0.01)

Net loss per share -

diluted ($0.00) ($0.00) ($0.00) ($0.01)

Weighted average

common shares

outstanding - basic 16,979,623 16,999,623 16,967,504 16,998,820

Weighted average

common shares

outstanding -

diluted 16,979,623 16,999,623 16,967,504 16,998,820

CONDENSED BALANCE SHEET

(Unaudited)

December 31, September 30,

2007 2008

Cash and marketable securities $8,804,000 $8,591,000

Other current assets 167,000 154,000

Total assets $8,971,000 $8,745,000

Current liabilities $128,000 $129,000

Minority interest in joint venture 11,000 24,000

Total stockholders' equity 8,832,000 8,592,000

Total liabilities and equity $8,971,000 $8,745,000


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
5. Dendreon Reports Third Quarter 2008 Financial Results
6. Osteotech Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
8. Oncothyreon reports third quarter 2008 financial results
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. NeurogesX Reports Third Quarter 2008 Results
11. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 21, 2017 , ... Premier executive recruitment firm, Slone Partners, is proud to ... Scanlon Media. , Hunt Scanlon Media is one of the most respected ... source in the human capital sector. , “It is a great honor for Slone ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced ... to be held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. ... Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel , March ... a leading developer of adult stem cell technologies for ... Chief Executive Officer, will provide an update on new ... nd Annual Neuroscience Biopartnering and Investment Forum, being ... York Academy of Sciences. ...
(Date:3/20/2017)... , ... March 20, 2017 ... ... that interfere with the ability of endogenous hormones to regulate homeostasis via ... binding activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
Breaking Biology News(10 mins):